The global Dengue Fever Treatment Market is expected to garner a market value of USD 877.82 Million in 2023 and is expected to accumulate a market value of USD 5435.25 Million by registering a CAGR of 20% in the forecast period 2023 to 2033. The market for Dengue Fever Treatment registered a CAGR of 11% in the historical period 2018 to 2022.
Studies state that in 2022, and as of 19 December, 3,766,153 cases and 3582 deaths have been reported. The majority of cases have been reported from Brazil (2,182,229), Vietnam (325 604), Philippines (201,509), India (110,473), and Indonesia (94,355).
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 877.82 Million |
| Anticipated Forecast Value (2033) | USD 5435.25 Million |
| Projected Growth Rate (2023 to 2033) | 20% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Dengue Fever Treatment reflected a value of 11% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering dengue fever treatments. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as the presence of reputed regional pharmaceutical giants.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for dengue fever treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dengue is fuelling market growth. Thus, the market for Dengue Fever Treatment is expected to register a CAGR of 20% in the forecast period 2023 to 2033.
Increased incidence of Dengue Cases to Push the Market Growth
According to the World Health Organization, the incidence of dengue has grown dramatically over recent decades. A vast majority of the cases are asymptomatic, mild, or self-managed, and hence the actual number of infections is highly under-reported. One modeling estimate indicates 390 Million dengue virus infections per year (95% credible interval 284-528 Million), of which 96 Million manifest clinically.
Another clinical study has established that nearly 4 billion people are at risk of infection. Despite a risk of infection existing in 129 countries, 70% of the actual burden is concentrated in Asia. Furthermore, the number of reported dengue cases over the past two decades has increased eightfold since the past 20 years, from 505,430 cases in 2000 to over 2.4 Million in 2019, with death rates climbing from 960 to 4032.
As of 2020, dengue continues to affect several countries, with the Americas reporting over 3 Million cases out of which 25,000 are classified as severe. High incidences were also reported across Bangladesh (101,000), Malaysia (131,000), the Philippines (420,000), and Vietnam (320,000). Hence, major pharmaceutical giants are accelerating the pace of their ongoing clinical trials, as well as initiating new ones so as to capitalize on this opportunity and expand their presence.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Dengue Fever Treatment, less awareness of Dengue Fever Treatment disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Improvement in healthcare spending propelling the growth of Dengue Fever Treatment in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Dengue Fever Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
India-based Serum Institute initiated a clinical trial in 2017 for verifying the efficacy of its VIS513 monoclonal antibody to treat dengue infections throughout the Indian subcontinent. The company holds exclusive licenses to the treatment for commercialization across all seven countries and has invested a sum of USD 5 million, which would yield an additional USD 34 million upon achievement of the set milestone.
Similarly, Sun Pharmaceutical Industries Ltd. has forged a partnership with the International Center for Genetic Engineering and Biotechnology (ICGEB) to develop a dengue vaccine that is safe, effective, and affordable. As per this agreement, Sun Pharma is funding and developing the DSV-4 vaccine candidate that targets all four serotypes of the dengue virus.
Technological Advancements Shaping Landscape for Dengue Fever Treatment in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
According to the Centers for Disease Control and Prevention (CDC), dengue outbreaks occasionally occur in the continental U.S.A. However, these outbreaks are common across its overseas territories, including Puerto Rico, the US Virgin Islands, and American Samoa respectively. On the mainland, outbreaks were frequent across Hawaii (2015), Florida (2013, 2020), and Texas (2013).
Between January 2010 and December 2017, a total of 5,387 dengue cases were reported. The majority of these were associated with travel (5,009; 93%), with the median patient age at 41 years. Over half of the cases (54%) were reported from five states: New York (18%), California (16%), Florida (14%), Texas (5%), and New Jersey (5%). This led to an overall hospitalization rate of 40%.
In May 2019, the US Food & Drug Administration approved the use of Sanofi’s Dengvaxia® live attenuated vaccine which is administered as three separate injections in 9-through-16-year-olds. In addition, existing trials for the ChimeriVaxTM Tetravalent Dengue Vaccine are expected to yield conclusive results in the future, paving the way for the entry of another potential vaccine candidate. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Vaccines as an effective treatment to drive the market
Dengue vaccine development has entered an important stage of its life cycle - with a host of pharmaceutical giants expected to present the results of their extensive clinical trials initiated in the past decade or half a decade. Considering these factors, vaccines are considered an effective treatment to account
Presently, Dengvaxia is being marketed by pharmaceutical giant Sanofi Pasteur and has been approved across 19 countries and the European Union. It also gained approval across the USA market in 2019. The vaccine is approximately 76% effective in preventing symptomatic, laboratory-confirmed dengue diseases in 9 through 16 years of age. Simultaneously, several other corporations are developing new vaccine candidates, thus generating immense revenue potential.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the dengue fever treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.
Key start-up players in the Dengue Fever Treatment Market are-
Key players in the Dengue Fever Treatment Market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 877.82 Million |
| Market Value in 2033 | USD 5435.25 Million |
| Growth Rate | CAGR of 20% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, End-User, Route of Administration, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, Gulf Cooperation Council, South Africa |
| Key Companies Profiled | Mylan N.V; Pfizer Inc.; Teva Pharmaceuticals USA, Inc.; Perrigo Company plc; GlaxoSmithKline plc; Dr. Reddy’s Laboratories Limited; Fresenius Kabi USA; Sun Pharmaceutical Industries Ltd.; ABIVAX; Aurobindo Pharma; Baxter; EMERGEX VACCINES; Hikma Pharmaceuticals PLC; Sanofi; and Takeda Pharmaceutical Company Limited |
| Customization | Available Upon Request |
Worldwide market is predicted to earn almost USD 877.82 million in 2023.
The global market could witness increment with 20% CAGR through 2033.
The overall market is projected to reach almost USD 5,435.25 million by 2033
Total adoption in North America could be around 25% of the global demand by 2033.
Vaccines segment accounts a sizeable portion of the overall market.
1. Executive Summary | Dengue Fever Treatment Market 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Drug 5.2. Vaccines 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Parenteral 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user 7.1. Hospitals 7.2. Homecare 7.3. Specialty Clinics 7.4. Others 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. MEA 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. GeneOne Life Science, Inc 16.2. Johnson & Johnson 16.3. Merck Sharp & Dohme Corp. 16.4. Novartis AG 16.5. Sanofi 16.6. Serum Institute of India Pvt. Ltd 16.7. Sun Pharmaceutical Industries Ltd. 16.8. Takeda Pharmaceutical Company Limited 16.9. Pfizer Inc. 16.10. Teva Pharmaceuticals 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Dengue Fever Treatment Market
